IMPACT JOURNALS LLC IMAGE: MECHANISM OF THE ANTITUMOR ACTIVITY OF THE RAD001 (EVEROLIMUS) + VOLASERTIB COMBINATION. CREDIT: CORRESPONDENCE TO – DIDIER DECAUDIN – [email protected] Oncotarget published “High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC” which reported that the aim of this study was therefore to define a combination...
